Trichomegaly and Poliosis of the Eyelashes During Cetuximab Treatment of Metastatic Colorectal Cancer

Rodriguez, Nelson A.; Ascaso, Francisco J.

doi:10.1200/jco.2011.34.6858

Cited by 28 publications

(11 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epidermal growth factor receptor (EGFR) inhibitors, used to treat various malignancies, result in keratin gene modulation and speculated increased terminal differentiation of hair 70 . Cetuximab, a monoclonal antibody that competitively inhibits EGFR, was noted to cause trichomegaly in numerous case reports of patients treated for malignancy 71–81 . Further, retrospective studies of cancer patients treated with Cetuximab noted eyelash trichomegaly as an AE in approximately 34% 82 to 37.5% of individuals 83 .…”

Section: Resultsmentioning

confidence: 99%

Eyelash trichomegaly: a systematic review of acquired and congenital aetiologies of lengthened lashes

Hutchison

Duffens

Yale

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

Long eyelashes have been popularized and many commercially available products exist to achieve eyelash growth as a desired cosmetic effect. Eyelash trichomegaly may be induced by medications, procedures, or be related to medical conditions; however, the exact mechanisms that govern eyelash growth are not well elucidated. This study aims to identify and summarize aetiologies associated with eyelash trichomegaly. We report a systematic review of 148 clinical trials, prospective and retrospective studies, and case reports describing all evidence‐based potential aetiologies of eyelash trichomegaly obtained from the Medline/PubMed and Cochrane Library through January 2021. Inclusion criteria were defined as (i) human studies involving congenital and acquired diseases in which eyelash trichomegaly is a characteristic or (ii) assessment of trichomegaly as an adverse or desired effect of a medication or procedure. Exclusion criteria included: animal studies, articles not available in English, outcomes unrelated to eyelash trichomegaly, and secondary review articles. Pharmacologic agents associated with eyelash trichomegaly included prostaglandin analogues (15‐keto fluprostenol isopropyl ester, bimatoprost, latanoprost, and travoprost), epidermal growth factor receptor inhibitors (cetuximab, erlotinib, and panitumumab), interferon‐alpha, and calcineurin inhibitors (tacrolimus and cyclosporine). Surgical procedures of the eyelid, as well as allergic rhinitis, atopic dermatitis, HIV, ichthyosis vulgaris (IV), uveitis, and vernal keratoconjunctivitis were also associated with increased eyelash growth. Congenital disorders associated with lengthened eyelashes included Cantú syndrome, CHOPS syndrome, Coffin–Siris syndrome, congenital heart disease, Cornelia de Lange syndrome, Costello syndrome, familial trichomegaly, Floating Harbor syndrome, Hermansky–Pudlak syndrome, Kabuki–Makeup syndrome, KBG syndrome, Oliver–McFarlane syndrome, Rubinstein–Taybi syndrome, and Smith–Magenis syndrome. While the most common cause of eyelash trichomegaly is topical bimatoprost use, better understanding of pathways implicated in eyelash trichomegaly may lead to the discovery of additional medications to stimulate eyelash growth and create avenues for future therapeutic interventions.

show abstract

Section: Resultsmentioning

confidence: 99%

Eyelash trichomegaly: a systematic review of acquired and congenital aetiologies of lengthened lashes

Hutchison

Duffens

Yale

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…1 Cetuximab, the first targeted therapy incorporated in metastatic colorectal cancer treatment, is an intravenously administered monoclonal antibody that binds selectively extracellular EGFR domain blocking signal transmission facilitating apoptosis of cancer cells. 2,5 Today, cetuximab is of important role in anti-cancer treatments of head and neck, colorectal, lung or other EGFR expressing solid tumors, post clinical trials consolidative of its unique precise action as monotherapy or combined with various cytotoxic drugs. 2 EGFR, although with pivotal participation in carcinogenesis, plays an equally vital role in normal skin development.…”

Section: Discussionmentioning

confidence: 99%

Pinnae and facial hypertrichosis induced by cetuximab

Alexandris

Alevizopoulos

Palamaris

et al. 2022

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Anti-EGFR targeted anti-cancer treatment is associated with various skin adverse events. Cetuximab is often associated with acneiform papules and skin disorders. Hypertrichosis cited in face pinnae and eyelash trichomegaly are seldom described. Case report A 72-year-old female cancer patient presented deteriorating facial-pinnae hypertrichosis and eyelash prolongation post cetuximab infusion. Management and outcome Consecutive cetuximab administration led to exaggerating hairy skin side effects, fully alleviated when the drug was discontinued. Discussion To the best of our knowledge, this is the first reported case of an anti-EGFR-associated diffuse pinnae hypertrichosis presentation in a female patient in literature. This distinct entity can be easily diagnosed and manipulated with early drug withdrawal. An extensive review of relevant basic molecular research is provided to increase physicians’ awareness.

show abstract

“…[ 4 5 ] Eyelashes may lose their normal curvature and became longer, the association of eyelashes’ trichomegaly with poliosis was also reported. [ 9 ]…”

Section: Discussionmentioning

confidence: 99%

Scanning electron microscopy of subclinical gefitinib-induced hair changes

et al. 2020

View full text Add to dashboard Cite

Oral inhibitors of epidermal growth factor receptor may have a wide range of cutaneous manifestations. Hair manifestations are observed in 10%–20% of the patients. At the ultrastructural level erlotinib-induced hair changes were already described as acquired pili torti et canaliculi. We examined a 78-year-old female patient, with lung carcinoma, taking gefitinib for 15 months. The treatment has no side effects with good tolerance and tumor response. Although the patient had not observed any change on the hairs under the therapy, some specimens were obtained to be examined in natura with scanning electron microscopy. Under low magnification incipient grooving was observed on the hair surface, tortions or angulations of the hair shaft were not found. With higher magnifications the surface grooving was even more evident. Our findings show that gefitinib may cause subclinical hair changes, similar to those described at the ultrastructural level with erlotinib.

show abstract

Trichomegaly and Poliosis of the Eyelashes During Cetuximab Treatment of Metastatic Colorectal Cancer

Cited by 28 publications

References 23 publications

Eyelash trichomegaly: a systematic review of acquired and congenital aetiologies of lengthened lashes

Eyelash trichomegaly: a systematic review of acquired and congenital aetiologies of lengthened lashes

Pinnae and facial hypertrichosis induced by cetuximab

Scanning electron microscopy of subclinical gefitinib-induced hair changes

Contact Info

Product

Resources

About